Skip to main content
Clinical Trials/NCT05076656
NCT05076656
Completed
Early Phase 1

Epigenetic and Microbiota Modifications in the Genesis of Adipose Tissue Dysfunction

Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud1 site in 1 country22 target enrollmentJune 10, 2019

Overview

Phase
Early Phase 1
Intervention
Lactobacillus fermentum D3
Conditions
Diabetes type2
Sponsor
Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud
Enrollment
22
Locations
1
Primary Endpoint
Changes in HOMA-IR
Status
Completed
Last Updated
3 years ago

Overview

Brief Summary

In order to investigate how gut microbiota interventions are able to change gut microbiota population and impact insulin resistance, 30 type2 diabetes volunteers with obesity will be randomized to one of the three treatment groups: 1) probiotics arm, who will take a Lactobacillus fermentum D3 in pills daily; 2) FMT arm, who will take a lyophilized fecal microbiota transplant in pills; and 3) control group, who will take placebo pills. After 3 months, insulin resistance, glucose metabolism parameters, and gut microbiota variation will be assessed.

Registry
clinicaltrials.gov
Start Date
June 10, 2019
End Date
June 30, 2022
Last Updated
3 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Sponsor
Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud
Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Type2 diabetes in treatment with metformin
  • 30 kg/m2≤IMC≤40 kg/m2
  • 30-70 years old
  • HOMA-IR \>6
  • Informed consent

Exclusion Criteria

  • psychopathologic alterations that do not permit the adherence to the trial.
  • Diabetes medication different from metformin.
  • History of cholecystectomy.
  • Use of Probiotics, and/or antibiotics in the last 3 months

Arms & Interventions

Probiotics arm

Individuals who receive a probiotics pill daily: Lactobacillus fermentum D3 (PCT/EP 2012058214)

Intervention: Lactobacillus fermentum D3

FMT arm

Individuals who receive a FMT in the form of pills with fecal material from a healthy donor.

Intervention: Fecal microbiota transplant (FMT)

Control arm

Individuals who receive a probiotics pill daily of placebo (milk powder)

Intervention: Placebo

Outcomes

Primary Outcomes

Changes in HOMA-IR

Time Frame: Baseline, 12 weeks

Homeostasis Model Assessment of fasting Insulin Resistance (HOMA-IR: glucose (mmol/l( x insulin (pmol/l)/22.5)

Secondary Outcomes

  • Changes in glucose metabolism(Baseline, 12 weeks)
  • Changes in gut microbiota(Baseline, 12 weeks)

Study Sites (1)

Loading locations...

Similar Trials